Comparison of Therapeutic Effects between Rivaroxaban and Dabigatran on Patients with Coronary Heart Disease and Atrial Fibrillation after Coronary Stent Implantation
Objective:To observe the effects of Rivaroxaban and Dabigatran in patients with coronary heart disease and atrial fibrillation after coronary stent implantation.Method:A total of 80 patients with coronary heart disease and atrial fibrillation who underwent coronary stent implantation in the Second People's Hospital of Jingdezhen from June 2021 to June 2023 were selected and randomly divided into two groups,with 40 cases in each group.Two groups were treated with Clopidogrel after operation,on this basis,group A was treated with Rivaroxaban and group B was treated with Dabigatran.The coagulation function[fibrinogen(FIB),prothrombin time(PT),platelet count(PLT)and D-dimer(D-D)],inflammatory factors[hypersensitive C reactive protein(hs-CRP)]before and after treatment,incidences of bleeding events,cardiovascular and cerebrovascular adverse events,adverse drug reactions and length of hospital stay were compared between the two groups.Result:Before treatment,there were no statistically significant differences in FIB,PT,PLT,D-D and hs-CRP between the two groups(P>0.05).After treatment,FIB,PT,PLT,D-D and hs-CRP in the two groups were lower than those before treatment,with statistically significant differences(P<0.05),but there were no statistically significant differences between the two groups(P>0.05).There were no statistically significant differences in the total incidences of bleeding events,cardiovascular and cerebrovascular adverse events,adverse drug reactions and hospital stay between the two groups(P>0.05).Conclusion:The application of Rivaroxaban or Dabigatran in patients with coronary heart disease and atrial fibrillation after coronary stent implantation can effectively improve coagulation function and inflammatory state,with comparable effects and safety.
国家科技期刊平台
NSTL
万方数据
